Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Core Viewpoint - Longeveron Inc. has launched a contract development and manufacturing business, which is expected to generate approximately $4-5 million in annual revenues, with its first contract signed with Secretome Therapeutics [1][2]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead investigational product being Lomecel-B™, an allogeneic medicinal signaling cell therapy [3]. - The company is pursuing multiple indications, including hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [3]. Manufacturing Facility - The new manufacturing services will operate from a 15,000 square feet state-of-the-art Good Manufacturing Practice (GMP) facility, which includes 3,000 square feet of cleanroom space and eight ISO 7 cleanrooms [1][2]. - The facility also features 1,150 square feet dedicated to process development, quality control, and warehousing [1]. Contract with Secretome Therapeutics - The first contract manufacturing agreement has been signed with Secretome Therapeutics, which is developing therapeutics from neonatal mesenchymal stem cells [1][2]. - This partnership aims to leverage Longeveron's cellular therapy manufacturing expertise to support the development of Secretome's lead product, STM-01, for chronic inflammatory diseases [2].